Tags

Type your tag names separated by a space and hit enter

Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.
Eur J Neurol. 2007 Mar; 14(3):282-9.EJ

Abstract

To evaluate the long-term effects of entacapone on both mean daily 'on' time and health-related quality of life (QoL) in patients with Parkinson's disease (PD) experiencing 'end-of-dose' motor fluctuations and the benefits of an early therapeutic intervention. A prospective, multicenter, observational, 12-month study was performed with an initial 3-month intervention phase, consisting of a phone call to half of the patients from randomly selected investigators to assess if dose adjustment was necessary. Effectiveness was determined by home diaries ('on' time), subscales II and III of the Unified Parkinson's Disease Rating Scale (UPDRS), and the Parkinson's Disease Questionnaire (PDQ-8). After 3 months of treatment, 4.0% of the intervention group patients discontinued the study, versus 18.4% in the control group (P < 0.01). The improvement in 'on' time was significantly increased since the 3-month visit (21%, P < 0.0001) until the end of the study (23% at 12 months, P < 0.0001). Entacapone also induced significant reductions in the UPDRS scores for subscales II and III and in the PDQ-8 score. 11.2% of patients experienced at least one adverse reaction. This study confirms the effectiveness of entacapone in reducing motor fluctuations by increasing 'on' time, and in improving QoL of PD patients. An early adjustment of entacapone and levodopa doses reduces the number of treatment discontinuations during the first months of treatment.

Authors+Show Affiliations

Department of Neurology, Hospital Universitario Gregorio Marañón, Madrid, Spain. fgrandasp@meditex.esNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17355548

Citation

Grandas, F, et al. "Long-term Effectiveness and Quality of Life Improvement in Entacapone-treated Parkinson's Disease Patients: the Effects of an Early Therapeutic Intervention." European Journal of Neurology, vol. 14, no. 3, 2007, pp. 282-9.
Grandas F, Hernández B, PRACTICOMT Study Group. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention. Eur J Neurol. 2007;14(3):282-9.
Grandas, F., & Hernández, B. (2007). Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention. European Journal of Neurology, 14(3), 282-9.
Grandas F, Hernández B, PRACTICOMT Study Group. Long-term Effectiveness and Quality of Life Improvement in Entacapone-treated Parkinson's Disease Patients: the Effects of an Early Therapeutic Intervention. Eur J Neurol. 2007;14(3):282-9. PubMed PMID: 17355548.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention. AU - Grandas,F, AU - Hernández,B, AU - ,, PY - 2007/3/16/pubmed PY - 2007/5/11/medline PY - 2007/3/16/entrez SP - 282 EP - 9 JF - European journal of neurology JO - Eur J Neurol VL - 14 IS - 3 N2 - To evaluate the long-term effects of entacapone on both mean daily 'on' time and health-related quality of life (QoL) in patients with Parkinson's disease (PD) experiencing 'end-of-dose' motor fluctuations and the benefits of an early therapeutic intervention. A prospective, multicenter, observational, 12-month study was performed with an initial 3-month intervention phase, consisting of a phone call to half of the patients from randomly selected investigators to assess if dose adjustment was necessary. Effectiveness was determined by home diaries ('on' time), subscales II and III of the Unified Parkinson's Disease Rating Scale (UPDRS), and the Parkinson's Disease Questionnaire (PDQ-8). After 3 months of treatment, 4.0% of the intervention group patients discontinued the study, versus 18.4% in the control group (P < 0.01). The improvement in 'on' time was significantly increased since the 3-month visit (21%, P < 0.0001) until the end of the study (23% at 12 months, P < 0.0001). Entacapone also induced significant reductions in the UPDRS scores for subscales II and III and in the PDQ-8 score. 11.2% of patients experienced at least one adverse reaction. This study confirms the effectiveness of entacapone in reducing motor fluctuations by increasing 'on' time, and in improving QoL of PD patients. An early adjustment of entacapone and levodopa doses reduces the number of treatment discontinuations during the first months of treatment. SN - 1468-1331 UR - https://www.unboundmedicine.com/medline/citation/17355548/Long_term_effectiveness_and_quality_of_life_improvement_in_entacapone_treated_Parkinson's_disease_patients:_the_effects_of_an_early_therapeutic_intervention_ L2 - https://doi.org/10.1111/j.1468-1331.2006.01635.x DB - PRIME DP - Unbound Medicine ER -